In this webcast, Paul Karila, Chief Business Officer, and Susanne Lardell, External Collaborations Manager, introduce a suite of native in vitro models developed by Cellectricon for the study of neuroplasticity. The Neuroplasticity Service Module allows for quantification of structural and functional changes at a scale required for drug discovery. Through case studies, it is demonstrated how the assays can be applied for screening of novel drugs and for elucidating mechanisms of action.

Abstract:

The incidence of neuropsychiatric disorders has increased dramatically over the past decades, necessitating continued efforts to identify drugs that will be safer and more efficacious than currently prescribed medications for conditions like depression.

Neuroplasticity is known to play a crucial role in the onset and progression of symptoms in a variety of psychiatric disorders. This relationship provides a handle for continued drug discovery to identify novel targets and molecules that affect neuroplasticity in vitro. However, quantification of neuroplasticity effects has been challenging due to low throughput and assay variability.

In this webcast, you will learn about a suite of native in vitro models developed by Cellectricon to study neuroplasticity. These highly-consistent models are capable of quantifying structural and functional changes at a scale required for drug discovery. Case studies will demonstrate how the assays can be applied for screening of novel drugs and for elucidating mechanisms of action. 

Learn how to:

  • Address challenges of low throughput and high variability for neuroplasticity research
  • Apply neuroplasticity in vitro models to prioritize molecules in the drug discovery process
  • Combine techniques such as optical electrophysiology and high content imaging to investigate neurobiological events from neuritogenesis to synaptogenesis and synaptic function

Presented by:

Paul Karila, PhD
Chief Business Officer at Cellectricon AB

Paul Karila, PhD, joined Cellectricon in 2012 as head of the company’s Discovery Services. He previously held leadership positions at the Departments of Molecular Pharmacology and Neuroscience at AstraZeneca. Paul earned his PhD in animal physiology from University of Gothenburg, Sweden, and was a Postdoctoral Fellow at University of Pittsburgh School of Medicine, USA.

 

Susanne Lardell
External Collaboration Manager and Senior Scientist at Cellectricon AB

Susanne joined Cellectricon in 2012 as External Collaborations Manager and Senior Scientist. Prior to joining Cellectricon, she was a Senior Research Scientist at AstraZeneca working in the department of Drug metabolism and Pharmacokinetics. Susanne has a MSc in Pharmaceutical Bioscience from University of Gothenburg, Sweden.